According to UOBKH, Tianjin Zhong Xin’s 1H FY20 revenue and earnings were slightly below expectations, forming 44.5% and 46.1% of its full-year forecasts, respectively.
Despite the impact from the novel coronavirus (Covid-19) lockdown measures, UOB KayHian is still bullish on Tianjin Zhong Xin Pharmaceutical Group Corp.
“We expect a strong rebound in 2H20 as China’s economy recovers and reopens,” UOBKH analysts Llelleythan Tan and John Cheong write in a note dated Aug 19.
